Health Care

Explore how EDAP TMS SA’s CFO and key executives hold and vest large share blocks, revealing confidence in HIFU growth and future valuation prospects.

Insider David Matlin’s $6.50 share buy + 133 k warrants signals bullish confidence; FDA review of CNM‑Au8 could unlock value near $13.50, while sales by other insiders hint at caution.

CEO insider buys 113,185 Cosmos Health shares, boosting confidence amid a PathMuscle partnership—yet investors weigh volatility, debt, and biotech risks.

Insider sale at Galectin Therapeutics reveals CEO liquidity needs and raises questions on future strategy, but the company’s key clinical milestones and competitive landscape remain critical for its valuation and growth.

Foresite Capital’s recent purchase of Alumis Inc. shares signals strong institutional confidence in its TYK2 inhibitor pipeline, offering investors insight into a clinical‑stage biotech’s future prospects.

Arcellx insider sale analysis: Christopher’s recent 6,131‑share sale at market price signals liquidity management, not a bearish trend, while investors should focus on the company’s adaptive immune therapy pipeline and technology‑driven value‑based …

Bridgebio CEO’s disciplined insider sales show confidence, yet the biotech’s 115 % YTD rise and strong pipeline keep it a top long‑term investment.

Zymeworks insider purchases signal confidence and disciplined capital use; learn how recent RSU activity, Phase 3 Ziihera results, and buy‑back plans could drive future value.

CEO Galbraith’s modest Zymeworks share purchase signals confidence in the company’s biotherapeutics pipeline, upcoming milestone payments, and long‑term growth prospects, offering investors reassurance amid market volatility.

Enliven Therapeutics insider trades show routine liquidity, not loss of confidence; the firm’s kinase‑inhibitor pipeline and neutral market sentiment suggest a buy‑or‑hold for long‑term investors.